NCT06281210 (BETTY-CRASY) is a NA clinical trial of Omission of surgical treatment in Breast Cancer, sponsored by European Institute of Oncology.

Who is sponsoring NCT06281210?

NCT06281210 is sponsored by European Institute of Oncology.

What drugs are being tested in NCT06281210?

Interventions in NCT06281210: Omission of surgical treatment.

What condition does NCT06281210 study?

NCT06281210 studies Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, Neoadjuvant Chemotherapy.

Is NCT06281210 still recruiting?

NCT06281210 is currently recruiting now. Last updated 28 February 2024.

Last reviewed 2024-02-28 · How we verify

NCT06281210: BETTY-CRASY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

Recruiting now NA Last updated 28 February 2024

What this trial tests

NA trial testing Omission of surgical treatment in Breast Cancer in 77 participants. Currently enrolling.

Timeline

11 December 2023

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	European Institute of Oncology
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	77
Start date	11 December 2023
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	2 locations across Italy

Drugs / interventions tested

Omission of surgical treatment

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
HER2-positive Breast Cancer — all drugs for HER2-positive Breast Cancer →
Neoadjuvant Chemotherapy — all drugs for Neoadjuvant Chemotherapy →

Sponsor

European Institute of Oncology

Who can join

18 and older, any sex, with Breast Cancer or Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant chemotherapy (NACT). The study design involves the histological confirmation of pCR using vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) guided by ultrasound. The primary objective is to demonstrate that the non-surgical, RT-only treatment and follow-up approach is not inferior to the traditional surgical approach in patients with pCR after NACT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other European Institute of Oncology trials

Trials by the same sponsor.

NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06281210 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
Last refreshed: 28 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06281210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing